Loading...
Market
Which organization will be the largest purchaser of the Bavarian Nordic mpox vaccine by December 31, 2024?
2
Resolution / Starting Odds
UK Government • 25%
Gavi • 25%
WHO • 25%
Other • 25%
Official purchasing records and announcements from Bavarian Nordic
Story
WHO Approves Bavarian Nordic Mpox Vaccine as UK and Gavi Ramp Up Efforts with 500,000 Doses
Sep 18, 2024, 09:15 AM
The World Health Organization (WHO) has granted its first authorization for the use of a vaccine against mpox in adults, marking a significant step in combating the disease in Africa. The vaccine, developed by Bavarian Nordic, is the first to be approved by WHO for containing the spread of mpox in African countries. In response to the outbreak, the UK has ordered over 150,000 doses of the Bavarian Nordic mpox vaccine to enhance its preparedness against a new strain of the virus. Furthermore, the global vaccine alliance Gavi has announced plans to purchase 500,000 doses of the Bavarian Nordic mpox vaccine, allocating $50 million for this initiative to support African countries hardest hit by the outbreak. The WHO declared the mpox outbreak in several African countries a public health emergency of international concern in August.
View original story
Similar markets
Nigeria • 25%
Kenya • 25%
South Africa • 25%
Other • 25%
Yes • 50%
No • 50%
Less than 1 million • 25%
1 to 3 million • 25%
3 to 5 million • 25%
More than 5 million • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Africa CDC • 25%
WHO • 25%
UNICEF • 25%
Other • 25%
Africa CDC • 25%
Gavi • 25%
WHO • 25%
Other • 25%
WHO • 25%
UNICEF • 25%
African Union • 25%
Other • 25%
Democratic Republic of Congo • 25%
Nigeria • 25%
South Africa • 25%
Other • 25%
Less than 30% • 25%
30% to 50% • 25%
50% to 70% • 25%
More than 70% • 25%
Less than 10 • 25%
10 to 20 • 25%
20 to 30 • 25%
More than 30 • 25%